The bone densitometer market was valued at USD 330.3 million in 2024 and is anticipated to expand at a CAGR of 4.7% from 2024 to 2030, reaching USD 441.3 million by 2030. This growth is attributed to a larger population dealing with kidney diseases, an increase in Vitamin D deficiency, a rise in knee osteoarthritis cases, and heightened public awareness of these issues and their solutions.
In December 2022, the FDA approved abaloparatide for managing osteoporosis in men. Previously, the Tymlos drug was used primarily for women, especially those who have undergone menopause and are at higher risk of fractures. Now, it is also approved for men. To ensure the safety and effectiveness of abaloparatide at a dose of 80 micrograms for men with osteoporosis, a double-blind, placebo-controlled study lasting 12 months was conducted. The availability of such treatments is expected to significantly boost market growth.
Key Insights
- In 2023, the axial bone densitometer segment held the largest revenue share of 65% due to its superior accuracy.
- The increasing number of osteoporotic patients is driving demand for axial bone densitometers.
- Central dual-energy X-ray absorptiometry is favored for its user-friendliness and safety for both children and adults.
- Axial bone densitometers are particularly popular for children due to their low error rate and non-invasive nature.
- Advantages of axial bone densitometers include low radiation exposure, patient comfort, and high precision.
- The osteoporosis and osteopenia diagnosis segment commands the largest market share, fueled by rising awareness and bone-related issues.
- Vitamin D and mineral deficiencies are contributing to bone problems, increasing the demand for bone densitometers.
- The growing prevalence of osteoporosis and osteopenia among menopausal women is driving demand.
- The cystic fibrosis diagnosis segment is expected to grow notably due to rising disease incidence, with approximately 40,000 cases in the U.S. and around 105,000 globally.
- Hospitals and diagnostic clinics are the primary end users, driven by a rising number of bone disease patients.
- Growth in hospitals is supported by the adoption of advanced healthcare systems, increased healthcare spending, and improved treatment access.
- Government investments in public health and advancements in healthcare services are boosting the market.
- Increased awareness of osteoporosis and its treatments, supported by campaigns and educational programs, is enhancing sales.
- National Osteoporosis Awareness and Prevention Month in May in the U.S. and similar initiatives in Canada and France promote bone health awareness.
- North America leads the bone densitometer market and is expected to maintain this position, reaching USD 0.17 billion by 2023.
- The U.S. market is projected to grow at a CAGR of 4.8% during the forecast period, supported by rising chronic disease cases, an aging population, robust medical infrastructure, and an improved healthcare system.
About P&S Intelligence
P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.
Contact:
Chandra Mohan
AVP – Business Development
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Follow Us: LinkedIn Twitter